García Montero, CieloFraile Martínez, OscarBravo Arribas, CoralTorres Carranza, DiegoSanchez Trujillo, LaraGómez Lahoz, Ana M.Guijarro, Luis G.García Honduvilla, NatalioAsúnsolo, AngelBujan, JuliaMonserrat, JorgeSerrano, EncarnaciónÁlvarez Mon, MelchorDe León Luis, Juan AntonioAlvarez Mon, Miguel ÁngelOrtega, Miguel A.2023-06-172023-06-172021-04-27García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines 2021;9:433. https://doi.org/10.3390/vaccines9050433.2076-393X10.3390/vaccines9050433https://hdl.handle.net/20.500.14352/7399This work was partially supported by grants from the Fondo de Investigación de la Seguridad Social, Instituto de Salud Carlos III (PI18/00912), Spain; Programa de Actividades de I+D de la Comunidad de Madrid en Biomedicina (B2017/BMD3804), Madrid, Spain; and Instituto de Salud Carlos III CIBER Enfermedades hepáticas y Digestivas, Spain.Since the worldwide COVID-19 pandemic was declared a year ago, the search for vaccines has become the top priority in order to restore normalcy after 2.5 million deaths worldwide, overloaded sanitary systems, and a huge economic burden. Vaccine development has represented a step towards the desired herd immunity in a short period of time, owing to a high level of investment, the focus of researchers, and the urge for the authorization of the faster administration of vaccines. Nevertheless, this objective may only be achieved by pursuing effective strategies and policies in various countries worldwide. In the present review, some aspects involved in accomplishing a successful vaccination program are addressed, in addition to the importance of vaccination in a pandemic in the face of unwillingness, conspiracy theories, or a lack of information among the public. Moreover, we provide some updated points related to the landscape of the clinical development of vaccine candidates, specifically, the top five vaccines that are already being assessed in Phase IV clinical trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, and CoronaVac).engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/vaccines9050433https://www.mdpi.com/2076-393X/9/5/433open access616.9SARS-CoV-2CoronavirusCOVID-19Vaccination programsVaccine acceptanceVaccine hesitancyPandemic managementmRNA vaccinesAdenovirus-based vaccinesInactivated virus vaccinesMedicinaEnfermedades infecciosas32 Ciencias Médicas3205.05 Enfermedades Infecciosas